Pulse Biosciences, Inc. 8-K Filing
Ticker: PLSE · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1625101
| Field | Detail |
|---|---|
| Company | Pulse Biosciences, Inc. (PLSE) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Pulse Biosciences, Inc. (ticker: PLSE) to the SEC on Dec 18, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (nge on Which Registered Common stock , $0.001 par value per share PLSE The Nasdaq).
How long is this filing?
Pulse Biosciences, Inc.'s 8-K filing is 2 pages with approximately 542 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-12-18 09:00:16
Key Financial Figures
- $0.001 — nge on Which Registered Common stock , $0.001 par value per share PLSE The Nasdaq
Filing Documents
- plse20251218_8k.htm (8-K) — 25KB
- ex_900505.htm (EX-99.1) — 13KB
- 0001437749-25-038213.txt ( ) — 170KB
- plse-20251218.xsd (EX-101.SCH) — 3KB
- plse-20251218_def.xml (EX-101.DEF) — 11KB
- plse-20251218_lab.xml (EX-101.LAB) — 15KB
- plse-20251218_pre.xml (EX-101.PRE) — 11KB
- plse20251218_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On December 18, 2025, Pulse Biosciences, Inc. (the "Company") issued a press release announcing the approval of its Investigational Device Exemption (IDE) submission by the U.S. Food and Drug Administration, allowing the Company to proceed with the initiation of its NANOPULSE-AF clinical study for the treatment of paroxysmal atrial fibrillation. The single-arm, multicenter, prospective, NANOPULSE-AF study is designed to demonstrate primary safety and effectiveness of the nPulse Cardiac Catheter System for the treatment of recurrent, drug-resistant, symptomatic, paroxysmal atrial fibrillation. Up to 30 sites, including three sites outside the United States, are planned to enroll up to 145 patients. A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Pulse Biosciences, Inc. dated December 18, 2025 - Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PULSE BIOSCIENCES, INC. Date: December 18, 2025 By: /s/ Paul A. LaViolette Paul LaViolette Chief Executive Officer (Principal Executive Officer)